A Phase I Study of ADG106 Administered in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2019
Price : $35 *
At a glance
- Drugs ADG 106 (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Adagene
- 11 Jan 2019 Status changed from planning to recruiting.
- 27 Jul 2018 New trial record
- 09 Jul 2018 According to Adagene media release, US FDA Approves Adagene IO Agonist IND for Solid Tumor and Non-Hodgkin Lymphoma Ph1 Trial.